Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab
Abstract Immune‐related adverse events (irAEs) are induced by immune checkpoint inhibitors (ICIs) which are administered for many cancers. There are many irAEs such as endocrine abnormalities, interstitial lung disease, and colitis. However, irAEs associated with type 2 (T2) inflammation are less kn...
Main Authors: | Hirofumi Watanabe, Kazuhiro Asada, Toshihiro Shirai, Hiroko Torii, Koji Yoshimura, Kimihide Kusafuka |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-10-01
|
Series: | Respirology Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/rcr2.638 |
Similar Items
-
Enhanced Interferon-β Response Contributes to Eosinophilic Chronic Rhinosinusitis
by: Yong Ju Jang, et al.
Published: (2018-10-01) -
Eosinophilic fasciitis induced by nivolumab therapy managed without treatment interruption or systemic immunosuppression
by: Ai-Tram N. Bui, BA, et al.
Published: (2020-08-01) -
Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
by: Takanori Numata, et al.
Published: (2019-10-01) -
Rapid and remarkable effectiveness of benralizumab for treating severe bronchial asthma with intractable eosinophilic rhinosinusitis and eosinophilic otitis media: A case report
by: Hideyasu Shimizu, et al.
Published: (2021-01-01) -
Efficacy and use of benralizumab in patients with eosinophilic chronic rhinosinusitis
by: G.L. Fadda, et al.
Published: (2021-03-01)